Kenvue (NYSE:KVUE) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Kenvue (NYSE:KVUE) released its earnings results on Tuesday. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.03, Briefing.com reports. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The firm had revenue of $2.89 billion during the quarter, compared to analyst estimates of $3.79 billion. The company’s quarterly revenue was down 24.9% on a year-over-year basis. Kenvue updated its FY24 guidance to $1.10-$1.20 EPS.

Kenvue Stock Up 1.5 %

Shares of KVUE traded up $0.31 during trading hours on Wednesday, hitting $20.39. The stock had a trading volume of 16,737,475 shares, compared to its average volume of 17,037,621. The firm has a 50 day simple moving average of $19.85 and a 200-day simple moving average of $20.11. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12. Kenvue has a 1-year low of $17.82 and a 1-year high of $27.80.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th will be paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 3.92%. The ex-dividend date is Tuesday, May 7th.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on KVUE. Sanford C. Bernstein began coverage on Kenvue in a research note on Thursday, April 11th. They issued an “underperform” rating and a $18.00 target price for the company. HSBC lifted their target price on shares of Kenvue from $20.00 to $21.00 and gave the company a “hold” rating in a research report on Wednesday. The Goldman Sachs Group began coverage on shares of Kenvue in a research note on Friday, March 1st. They set a “neutral” rating and a $20.00 price target for the company. JPMorgan Chase & Co. lowered their price objective on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 9th. Finally, Royal Bank of Canada lowered their target price on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Kenvue currently has a consensus rating of “Hold” and a consensus target price of $24.38.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.